Analystreport

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $62.00 price target on the stock.

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations